Curbing the opioid epidemic in the United States: The risk evaluation and mitigation strategy (REMS)

JAMA

Volumn 308, Issue 5, 2012, Pages 457-458

  Nelson, Lewis S ^a   Perrone, Jeanmarie ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; OPIATE; NARCOTIC ANALGESIC AGENT;

CANCER PAIN; CERTIFICATION; CHRONIC PAIN; CONTINUING EDUCATION; CONTRACT; DRUG FATALITY; DRUG FORMULATION; DRUG INFORMATION; DRUG LABELING; DRUG LEGISLATION; DRUG MARKETING; DRUG MONITORING; DRUG OVERDOSE; DRUG PACKAGING; DRUG SAFETY; EPIDEMIC; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HUMAN; LABORATORY TEST; LOZENGE; MANDATORY PROGRAM; MANDATORY TESTING; OPIATE ADDICTION; PATIENT EDUCATION; POSTMARKETING SURVEILLANCE; POSTOPERATIVE PAIN; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SHORT SURVEY; UNITED STATES; ARTICLE; CLINICAL PRACTICE; DRUG CONTROL; GOVERNMENT REGULATION; INTOXICATION; LEGAL ASPECT; METHODOLOGY; OFF LABEL DRUG USE; PAIN; PATIENT CARE; RISK ASSESSMENT; STANDARD;

ANALGESICS, OPIOID; DRUG AND NARCOTIC CONTROL; EPIDEMICS; GOVERNMENT REGULATION; HUMANS; OFF-LABEL USE; OPIOID-RELATED DISORDERS; OVERDOSE; PAIN; PATIENT CARE; PHYSICIAN'S PRACTICE PATTERNS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84864517110     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.8165     Document Type: Short Survey

References (10)

1. Chou R, Fanciullo GJ, Fine PG, et al American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
2. Centers for Disease Control and Prevention. CDC grand rounds: prescription drug overdoses - a US epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10-13.
3. Zgierska A, Miller M, Rabago D. Patient satisfaction, prescription drug abuse, and potential unintended consequences. JAMA. 2012;307(13):1377-1378.
4. Centers for Disease Control and Prevention. Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010;59(23):705-709.
5. US Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting opioids. http://www.fda.gov/Drugs/ DrugSafety/InformationbyDrugClass/ucm163647.htm. Accessed July 11, 2012.
6. US Food and Drug Administration. Summaryminutes of the Joint Meeting of the Anesthetic and Life Support Drugs AdvisoryCommittee (ALSDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM), July 22-23, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM224672.pdf. Accessed June 1, 2012.
7. Wolf MS, King J, Wilson EA, et al. Usability of FDA-approved medication guides [published online May 8, 2012]. J Gen Intern Med. doi:10.1007/s11606-012- 2068-7.
8. Purdue Pharma. OxyContin REMS website. http://www.oxycontinrems.com. Accessed June 7, 2012.
9. Gugelmann HM, Perrone J. Can prescription drug monitoring programs help limit opioid abuse? JAMA. 2011;306(20):2258-2259.
10. Slevin KA, Ashburn MA. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies. J Opioid Manag. 2011;7(2):109-115.